A Bioluminescent Imaging Mouse Model for Marburg Virus Based on a Pseudovirus System

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2017 May 9

PMID 28481728

Citations 27

Authors

Li Zhang

Qianqian Li

Qiang Liu

Weijin Huang

Jianhui Nie

Youchun Wang

Affiliations

Soon will be listed here.

Abstract

Marburg virus (MARV) can cause lethal hemorrhagic fever in humans. Handling of MARV is restricted to high-containment biosafety level 4 (BSL-4) facilities, which greatly impedes research into this virus. In this study, a high titer of MARV pseudovirus was generated through optimization of the HIV backbone vectors, the ratio of backbone vector to MARV glycoprotein expression vector, and the transfection reagents. An in vitro neutralization assay and an in vivo bioluminescent imaging mouse model for MARV were developed based on the pseudovirus. Protective serum against MARV was successfully induced in guinea pigs, which showed high neutralization activity in vitro and could also protect Balb/c mice from MARV pseudovirus infection in vivo. This system could be a convenient tool to enable the evaluation of vaccines and therapeutic drugs against MARV in non-BSL-4 laboratories.

Citing Articles

A surrogate BSL2-compliant infection model recapitulating key aspects of human Marburg virus disease.

Yang W, Zhou W, Liang B, Hu X, Wang S, Wang Z Emerg Microbes Infect. 2025; 14(1):2449083.

PMID: 39745141 PMC: 11727069. DOI: 10.1080/22221751.2024.2449083.

[Development of a new platform for testing antiviral drugs using coronavirus-infected human nasal mucosa organoids].

Yu Y, Cao J, Liu R, Zhou M, Wei J, Zheng H Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(11):2227-2234.

PMID: 39623279 PMC: 11605208. DOI: 10.12122/j.issn.1673-4254.2024.11.20.

Natural products as a source of Coronavirus entry inhibitors.

Szabo D, Crowe A, Mamotte C, Strappe P Front Cell Infect Microbiol. 2024; 14:1353971.

PMID: 38449827 PMC: 10915212. DOI: 10.3389/fcimb.2024.1353971.

Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study.

Zheng W, Cao X, Luo J, Liu Z, Que W, Guo X Neurol Sci. 2023; 45(4):1707-1717.

PMID: 37940750 DOI: 10.1007/s10072-023-07186-w.

Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus.

Sang Y, Zhang Z, Liu F, Lu H, Yu C, Sun H Signal Transduct Target Ther. 2023; 8(1):172.

PMID: 37117161 PMC: 10144886. DOI: 10.1038/s41392-023-01432-5.

References

Ozaki D, Gao H, Todd C, Greene K, Montefiori D, Sarzotti-Kelsoe M . International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials. PLoS One. 2012; 7(1):e30963. PMC: 3267749. DOI: 10.1371/journal.pone.0030963. View

Nie J, Wang W, Wen Z, Song A, Hong K, Lu S . Optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China. J Virol Methods. 2012; 185(2):267-75. DOI: 10.1016/j.jviromet.2012.07.011. View

Bausch D, Nichol S, Muyembe-Tamfum J, Borchert M, Rollin P, Sleurs H . Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med. 2006; 355(9):909-19. DOI: 10.1056/NEJMoa051465. View

Warfield K, Bradfute S, Wells J, Lofts L, Cooper M, Alves D . Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol. 2009; 83(13):6404-15. PMC: 2698517. DOI: 10.1128/JVI.00126-09. View

Shimojima M, Takada A, Ebihara H, Neumann G, Fujioka K, Irimura T . Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol. 2006; 80(20):10109-16. PMC: 1617303. DOI: 10.1128/JVI.01157-06. View

Brauburger K, Hume A, Muhlberger E, Olejnik J . Forty-five years of Marburg virus research. Viruses. 2012; 4(10):1878-927. PMC: 3497034. DOI: 10.3390/v4101878. View

Zinn K, Chaudhuri T, Szafran A, OQuinn D, Weaver C, Dugger K . Noninvasive bioluminescence imaging in small animals. ILAR J. 2008; 49(1):103-15. PMC: 2614121. DOI: 10.1093/ilar.49.1.103. View

Yermolina M, Wang J, Caffrey M, Rong L, Wardrop D . Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry. J Med Chem. 2011; 54(3):765-81. PMC: 3081529. DOI: 10.1021/jm1008715. View

Todd C, Greene K, Yu X, Ozaki D, Gao H, Huang Y . Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. J Immunol Methods. 2011; 375(1-2):57-67. PMC: 3332116. DOI: 10.1016/j.jim.2011.09.007. View

10.

Manicassamy B, Wang J, Rumschlag E, Tymen S, Volchkova V, Volchkov V . Characterization of Marburg virus glycoprotein in viral entry. Virology. 2006; 358(1):79-88. DOI: 10.1016/j.virol.2006.06.041. View

11.

Ascenzi P, Bocedi A, Heptonstall J, Capobianchi M, Di Caro A, Mastrangelo E . Ebolavirus and Marburgvirus: insight the Filoviridae family. Mol Aspects Med. 2007; 29(3):151-85. DOI: 10.1016/j.mam.2007.09.005. View

12.

Hensley L, Alves D, Geisbert J, Fritz E, Reed C, Larsen T . Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques. J Infect Dis. 2011; 204 Suppl 3:S1021-31. DOI: 10.1093/infdis/jir339. View

13.

Glaze E, Roy M, Dalrymple L, Lanning L . A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the 'Animal Rule'. Comp Med. 2015; 65(3):241-59. PMC: 4485633. View

14.

MATUMOTO M . A note on some points of calculation method of LD50 by Reed and Muench. Jpn J Exp Med. 1949; 20(2):175-9. View

15.

Swanepoel R, Smit S, Rollin P, Formenty P, Leman P, Kemp A . Studies of reservoir hosts for Marburg virus. Emerg Infect Dis. 2008; 13(12):1847-51. PMC: 2876776. DOI: 10.3201/eid1312.071115. View

16.

Bente D, Gren J, Strong J, Feldmann H . Disease modeling for Ebola and Marburg viruses. Dis Model Mech. 2009; 2(1-2):12-7. PMC: 2615158. DOI: 10.1242/dmm.000471. View

17.

Yaddanapudi K, Palacios G, Towner J, Chen I, Sariol C, Nichol S . Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J. 2006; 20(14):2519-30. DOI: 10.1096/fj.06-6151com. View

18.

Basu A, Li B, Mills D, Panchal R, Cardinale S, Butler M . Identification of a small-molecule entry inhibitor for filoviruses. J Virol. 2011; 85(7):3106-19. PMC: 3067866. DOI: 10.1128/JVI.01456-10. View

19.

Sinn P, Hickey M, Staber P, Dylla D, Jeffers S, Davidson B . Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J Virol. 2003; 77(10):5902-10. PMC: 154009. DOI: 10.1128/jvi.77.10.5902-5910.2003. View

20.

Peterson A, Bauer J, Mills J . Ecologic and geographic distribution of filovirus disease. Emerg Infect Dis. 2004; 10(1):40-7. PMC: 3322747. DOI: 10.3201/eid1001.030125. View